Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

ClinicalTrials.gov ID: NCT05098132

Public ClinicalTrials.gov record NCT05098132. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 2:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2 Study to Evaluate STK-012 as a Single Agent and in Combination Therapy in Subjects With Front-line Advanced NSCLC and Other Selected Indications

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a randomized study of STK-012 in combination with standard of care (SoC) pembrolizumab, pemetrexed, and carboplatin versus SoC, in patients with first line, PD-L1 negative or STK11 mutated, non-squamous, non-small cell lung cancer.

Study identification

NCT ID: NCT05098132
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Synthekine; Industry
Enrollment: 364 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 24, 2022
Primary completion: Dec 31, 2028
Completion: Dec 31, 2028
Last update posted: Jul 20, 2026

2022 – 2029

United States locations

U.S. sites: 33
U.S. states: 18
U.S. cities: 29

Facility	City	State	ZIP	Site status
University of Arizona Cancer Center	Tucson	Arizona	85721	Recruiting
Beverly Hills Cancer Center	Beverly Hills	California	90211	Recruiting
Providence Medical Foundation	Fullerton	California	92835	Recruiting
UC San Diego Moores Cancer Center	La Jolla	California	92093-0698	Active, not recruiting
Cedars Sinai	Los Angeles	California	90048	Recruiting
Hoag Memorial Hospital Presbyterian	Newport Beach	California	92663	Recruiting
UCLA Hematology/Oncology - Santa Monica	Santa Monica	California	90404	Recruiting
Yale New Haven Hospital, Yale Cancer Center	New Haven	Connecticut	06510	Recruiting
Georgetown University	Washington D.C.	District of Columbia	20057	Recruiting
Winship Cancer Institute, Emory University	Atlanta	Georgia	30322	Recruiting
University of Chicago	Chicago	Illinois	60637	Recruiting
University of Maryland	Baltimore	Maryland	21201	Recruiting
Massachusetts General Hospital	Boston	Massachusetts	02114	Recruiting
Beth Israel Deaconess Medical Center	Boston	Massachusetts	02215	Recruiting
Dana-Farber Cancer Institute	Boston	Massachusetts	02215	Recruiting
HealthPartners Cancer Center at Regions Hospital	Saint Paul	Minnesota	55101	Recruiting
Northwell Health	Lake Success	New York	11042	Recruiting
NYU Langone Health	New York	New York	10016	Recruiting
Columbia University Irving Medical Center	New York	New York	10032	Active, not recruiting
Memorial Sloan-Kettering Cancer Center	New York	New York	10065	Recruiting
Duke Cancer Center	Durham	North Carolina	27710	Active, not recruiting
University Hospitals Cleveland	Cleveland	Ohio	44106	Recruiting
The James Cancer Hospital and Solove Research Institute	Columbus	Ohio	43210	Recruiting
Providence Cancer Institute	Portland	Oregon	97123	Recruiting
Fox Chase Cancer Center	Philadelphia	Pennsylvania	19111	Recruiting
UPMC Hillman Cancer Center	Pittsburgh	Pennsylvania	15232	Terminated
Baptist Memorial Hospital Cancer Center	Memphis	Tennessee	38120	Active, not recruiting
Sarah Cannon Research Institute - Nashville	Nashville	Tennessee	37203	Active, not recruiting
Renovatio Clinical	El Paso	Texas	79915	Withdrawn
Oncology Consultants	Houston	Texas	77303	Recruiting
Renovatio Clinical	The Woodlands	Texas	77380	Withdrawn
NEXT Virginia	Fairfax	Virginia	22031	Recruiting
Northwest Medical Specialties	Tacoma	Washington	98405	Active, not recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05098132, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 20, 2026 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05098132 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →